BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 18, 2016--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Amar
Sawhney, Ph.D., President and Chief Executive Officer, will present at
two upcoming investor conferences:
-
2016 RBC Capital Markets Global Healthcare Conference
Wednesday,
February 24, 2016 at 4:05 p.m. Eastern Time
The New York Palace
Hotel, New York, NY
-
36th Annual Cowen and Company Healthcare Conference
Monday,
March 7, 2016 at 1:20 p.m. Eastern Time
The Boston Marriott
Copley Place, Boston, MA
Live audio webcasts of the presentations can be accessed through the
Calendar of Events section of the Company's website at
investors.ocutx.com. Replays of the webcasts will be available on the
Company's website for two weeks following each presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix's lead product candidate,
DEXTENZA™, is in Phase 3 clinical development for post-surgical ocular
inflammation and pain and allergic conjunctivitis, and in Phase 2
clinical development for inflammatory dry eye disease. An NDA for the
post-operative ocular pain indication has been accepted by the FDA with
a PDUFA date of July 24, 2016. A third Phase 3 clinical trial is being
conducted for post-operative ocular inflammation and pain. For glaucoma
and ocular hypertension, OTX-TP (sustained release travoprost)
intracanalicular depot, has completed a Phase 2b clinical trial. Ocular
Therapeutix is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal
incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160218005306/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com
